- PLAcental Circulation and pre-Eclampsia outcomes uNder the Treatment with Arginine (PLACENTA): а multicenter randomized controlled trial
PLAcental Circulation and pre-Eclampsia outcomes uNder the Treatment with Arginine (PLACENTA): а multicenter randomized controlled trial
HEALTH OF WOMAN. 2019.6(142): 20–26; doi 10.15574/HW.2019.142.20
Kim En-Din1, F.P. Nishanova1, A.Kh. Karimov2, A.S. Liubchich3
1Republican Specialized Scientific and Practical Medical Center of Obstetrics and Gynecology Ministry of Health of the Republic of Uzbekistan, Tashkent
2Tashkent Medical Academy, Tashkent
3Republican Perinatal Center of the Republic of Uzbekistan, Tashkent
The objective: to evaluate the effectiveness of L-arginine in the correction of dysfunction in the utero-placental-fetal complex, intrauterine development of the fetus and the condition of the newborn in the early period of adaptation.
Materials and methods. A prospective double-blind, randomized, multicenter controlled clinical trial was carried out at the Republican Specialized Scientific and Practical Medical Center of Obstetrics and Gynecology, II Clinic of the Tashkent Medical Academy and the Republican Perinatal Center of the Ministry of Health of the Republic of Uzbekistan.
Results. Treatment with L-arginine in women at the end of the second and beginning of the third trimester of pregnancy with chronic diseases complicated by placental dysfunction improves perinatal outcomes, leads to a decrease in the number of premature births and asphyxiation of newborns.
Conclusion. The use of L-arginine in the treatment of preeclampsia and correction of disorders in the utero-placental-fetal complex significantly improves the utero-placental-fetal blood flow. This allows to prolong the pregnancy to the optimal term of delivery.
Key words: utero-placental-fetal blood flow, placental dysfunction, fetoplacental insufficiency, pregnant women, newborns, correction, therapy, L-arginine, Tivortin.
REFERENCES
1. Babushkina AV. 2009. L-arginin s tochki zreniya dokazatelnoy meditsinyi. Redaktsiya «Ukrainskogo meditsinskogo zhurnala» 6 (74) XI XII: 43–48.
2. Golovchenko YuI, Treschinskaya MA. 2008. Obzor sovremennyih predstavleniy ob endotelialnoy disfunktsii. Consilium medicum Ukraina 11: 38–40.
3. Stepanov YuM, Kononov IN, Zhurbina AI, Filippova AYu. 2004. Arginin v meditsinskoy praktike. Zhurn. AMN UkraYini 10(1): 340–352.
4. Zhenilo VM, Mihno IV. 2004. Reaktsiya tsitokinovoy sistemyi u rozhenits s tyazhelyim gestozom na operatsionnyiy stress pri regionarnoy anestezii. II Vserossiyskaya mezhdistsiplinarnaya nauchno-prakticheskaya konferentsiya. Kriticheskie sostoyaniya v akusherstve i neonatologii. Petrozavodsk, 7–10 iyunya: 255–258.
5. Kim En – Din, Nishanova FP, Kulichkin YuV. 2017. Nekotoryie aspektyi korrektsii sistemnogo vospalitelnogo otveta u patsientok s preeklampsiey. Zdorove Uzbekistana 11 (22): 28 32.
6. Klinicheskoe rukovodstvo po vedeniyu bolnyih s gipertenzivnyim sindromom pri beremennosti. Tsentr dokazatelnoy meditsinyi. Tashkent: 63. 2007.
7. Medvedev BI, Syundyukova EG, Sashenkov SL. 2013. Kliniko biohimicheskie prediktoryi razvitiya preeklampsii. Akusherstvo i ginekologiya 5:30 35.
8. Milovanov AI. 1999. Patologiya sistemyi mat platsenta plod. M, Meditsina: 446.
9. Nishanova FP, Kim En–Din, Kulichkin YuV, Tadzhidinov EE. 2018. Effektivnost donatorov oksida azota pri korrektsii matochno-platsentarnogo i fetoplatsentarnogo krovotoka u patsientok s preeklampsiey. Vestnik dermatologii i venerologii i reproduktivnogo zdorovya 1 2 (81 82): 6–10.
10. Ostrovskiy VK, Maschenko AV, Yangolenko DV, Makarov SV. 2006. Pokazateli krovi i leykotsitarnogo indeksa intoksikatsii v otsenke tyazhesti i opredelenii prognoza pri vospalitelnyih, gnoynyh i gnoyno-destruktivnyih zabolevaniyah. Klin. lab. diagnostika 6: 50–53.
11. Petrischev NE, Berkovich OA, Vlasov ED i dr. 2001. Diagnosticheskaya tsennost opredeleniya deskvamirovannyih endotelialnyih kletok krovi. Klin. lab. diagnostika 1:50 52.
12. Stepanov YuM, Kononov IN, Zhurbina AI, Filippova AYu. 2004. Arginin v meditsinskoy praktike. Zhurn. AMN Ukrainу 10 (1): 340–352.
13. Lutsenko NS, Evtereva IA, Geraskina LR i dr. 2011. Tivortin v terapii platsentarnoy disfunktsii. Zdorove zhenschiny 10 (66): 32 33.
14. Böger RH. 2007. The pharmacodynamics of L-arginine. J. Nutr. 137: 1650–1655. https://doi.org/10.1093/jn/137.6.1650S; PMid:17513442
15. Facchinetti F, Saade GR, Neri I et al. 2007. L-arginine supplementation in patients with gestational hypertension: a pilot study. Hypertens Pregnancy: 26 (1). https://doi.org/10.1080/10641950601147994; PMid:17454224
16. Felipe V еt al. 2012. Lechebnoe deystvie L-arginina i antioksidantnyih vitaminov pri lechenii preeklampsii u zhenschin gruppyi povyishennogo riska: randomizirovannoe kontroliruemoe issledovanie. Zdorove zhenschiny 2 (68): 41–48.
17. Gilbert JS, Nijland MJ, Knoblich P. 2008. Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev. Cardiovasc. Ther. 6(10): 1367–1377. https://doi.org/10.1586/14779072.6.10.1367; PMid:19018690 PMCid:PMC2650232
18. Neri I, Jasonni VM, Gori GF et al. 2006. Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. J. Matern. Fetal Neonatal. Med. 19(5): 277–281. https://doi.org/10.1080/14767050600587983; PMid:16753767
19. Rytlewski K, Olszanecki R, Lauterbach R et al. 2006. Effects of oral L-arginine on the foetal condition and neonatal outcome in preeclampsia: a preliminary report. Basic Clin. Pharmacol. Toxicol. 99 (2): 146–152. https://doi.org/10.1111/j.1742-7843.2006.pto_468.x; PMid:16918716
20. Zhang N, Xiong AH, Xiao X, Li LP. 2007. Effect and mechanism of L-arginine therapy for fetal growth retardation due to pregnancy‑induced hypertension. Nan. Fang Yi Ke Da Xue Xue Bao. 27 (2): 198–200.